In this study, a novel, point-of-care style μPAD (microfluidic paper-based diagnostic) for influenza has been developed with the ability to determine antiviral susceptibility of the strain for treatment decision. 
μPAD
Development of a point-of-care diagnostic for influenza detection with antiviral treatment effectiveness indication.Currently, diagnosis of influenza is performed either through tedious polymerase chain reaction (PCR) or through rapid antigen detection assays. 
polymerase chain reaction (PCR)
Development of a point-of-care diagnostic for influenza detection with antiviral treatment effectiveness indication.Currently, diagnosis of influenza is performed either through tedious polymerase chain reaction (PCR) or through rapid antigen detection assays.  The rapid antigen detection assays available today are highly specific but not very sensitive, and most importantly, lack the ability to show if the strain of influenza detected is susceptible to antiviral agents, such as Tamiflu and Relenza. 
rapid antigen detection assays